



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Phenotypic Characterisation of Bovine Alveolar Macrophages Reveals Two Major Subsets with Differential Expression of CD163

Citation for published version:

Charlton, E, Sopp, P, Raper, A, Dry, I, Burdon, T, Hope, J & Waddell, L 2024, 'Phenotypic Characterisation of Bovine Alveolar Macrophages Reveals Two Major Subsets with Differential Expression of CD163', *Scientific Reports*, vol. 14, 14974, pp. 1-9. <https://doi.org/10.1038/s41598-024-65868-7>

Digital Object Identifier (DOI):

[10.1038/s41598-024-65868-7](https://doi.org/10.1038/s41598-024-65868-7)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Scientific Reports

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Phenotypic Characterisation of Bovine Alveolar Macrophages Reveals Two Major**
2 **Subsets with Differential Expression of CD163**

3

4 Emily M. Randall¹, Paul Sopp², Anna Raper¹, Inga Dry¹, Tom Burdon¹, Jayne C. Hope^{1*} and
5 Lindsey A. Waddell¹

6

7 ¹The Roslin Institute, Easter Bush, Edinburgh, EH25 9RG, UK.

8 ²MRC Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, Oxford, OX39DS,
9 UK.

10

11 *Corresponding author jayne.hope@roslin.ed.ac.uk

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27 Abstract

28 Bovine alveolar macrophages (AMs) defend the lungs against pathogens such as
29 *Mycobacterium bovis* (*M. bovis*), the causative agent of bovine tuberculosis. However, little is
30 known about the surface molecules expressed by bovine AMs and whether there is
31 heterogeneity within the population. The purpose of this study was to characterise the bovine
32 AM cell surface phenotype using flow cytometry.

33 Bronchoalveolar lavage (BAL) samples from four different calves were stained with a
34 combination of antibodies against immune cell molecules prior to flow cytometric analysis. To
35 assess the degree of expression, we considered the distribution and relative intensities of
36 stained and unstained cells.

37 We demonstrated that bovine AMs have high expression of CD172a, ADGRE1,
38 CD206, and CD14, moderate expression of CD80, MHC II, CD1b, and CD40, low expression
39 of CX3CR1 and CD86, and little or no expression of CD16 and CD26. Two distinct subsets of
40 bovine AMs were identified based on CD163 expression. Subsequent analysis showed that
41 the CD163⁺ subset had greater expression of other typical macrophage molecules compared
42 to the CD163⁻ subset, suggesting that these cells may perform different roles during infection.

43 The characterisation of the uninfected bovine AM phenotype will provide a foundation
44 for the examination of *M. bovis*-infected AMs.

45

46

47

48

49

50

51

52 Introduction

53 *Mycobacterium bovis* is the pathogen responsible for bovine tuberculosis, a significant
54 global disease which impacts both animal and human health. Alveolar macrophages (AMs)
55 are the first line of defence against *M. bovis* and the early interactions between host and
56 pathogen are crucial in determining the outcome of infection [1]. Despite this, little is known
57 about the phenotypic diversity of bovine AMs, including the cell surface molecules present.

58 Knowledge of the bovine AM phenotype is essential for understanding infections that
59 target this immune cell and may provide important insights for disease control. We previously
60 used single colour flow cytometry to describe bovine AMs [2], and here we significantly extend
61 these findings using multi-colour analyses to include detection of additional molecules for
62 which we have recently generated new reagents. This includes ADGRE1, the large animal
63 homologue of murine F4/80; a G protein-coupled receptor (GPCR) with seven transmembrane
64 domains and an extracellular region consisting of EGF-like repeats [3]. In mice, F4/80,
65 encoded by the *Adgre1* gene, has been used as a marker for tissue-resident macrophages,
66 although this does not include murine AMs which express low levels of F4/80 [4; 5]. The AMs
67 of other animal species, however, have shown high levels of ADGRE1. In the pig, AMs express
68 ADGRE1 at the cell surface, and ADGRE1 was hypothesised to function as a pattern
69 recognition receptor. Based on RNA-Seq data, the expression of ADGRE1 in human, sheep,
70 and buffalo AMs varies between the different species, but the degree of expression in bovine
71 AMs was not measured [6].

72 Another seven transmembrane GPCR found on the cell surface is the fractalkine
73 receptor, CX3CR1, which regulates macrophage function at inflammatory sites [7]. Like
74 mouse and human monocytes, bovine non-classical monocytes have high CX3CR1 gene
75 expression which likely aids migration into inflamed tissues, whereas classical monocytes
76 have low expression [8; 9]. In the murine lung, interstitial macrophages are CX3CR1 positive
77 whilst AMs are CX3CR1 negative [10]. Detection of CX3CR1 expression on the surface of

78 bovine AMs through use of the fluorescently labelled single ligand, CX3CL1, as a molecular
79 tag for receptor expression enables further studies of this molecule.

80 The mannose receptor, CD206, has been used as a marker for the M2, anti-
81 inflammatory macrophage state. Both human and murine AMs express high levels of CD206
82 in the normal, healthy lung [11; 12]. Human AMs also variably express the M2 related molecule
83 CD163. These macrophages can be divided into high CD163 and intermediate CD163
84 subpopulations. It has been speculated that the heterogeneity in CD163 expression may be
85 due to a mix of tissue-resident and monocyte-derived macrophages in the population, or to
86 different anatomical positions or activation states [11].

87 The heterogeneity of the AM population becomes more pronounced when
88 macrophages are exposed to pathogen associated molecular patterns. Activated
89 macrophages upregulate pro-inflammatory genes and those involved in antigen presentation.
90 This includes MHC class II and CD1b which present peptide and lipid antigens respectively to
91 T-cells. The co-stimulatory molecules, CD80 and CD86, are also upregulated as they are
92 necessary for T-cell activation. These pro-inflammatory M1 macrophages also upregulate
93 CD40 which enhances their activity via interaction with CD40L on T-cells [13]. It is likely that
94 the characteristics, diversity, and abundance of AM populations change over time depending
95 upon the microenvironment. In the murine lung, M2 macrophage subpopulations dominate
96 prior to inflammation. The induction of inflammation leads to an increase in M1 macrophage
97 subpopulations which subsequently almost disappear during the resolution of inflammation
98 [14]. Understanding how AM populations change in cattle during *M. bovis* infection could
99 provide significant insight into the early host-pathogen interactions that control the outcome of
100 exposure and pinpoint targets for intervention.

101 Few studies have analysed bovine AMs by flow cytometry. However, it has been
102 shown that the majority of cells in BAL fluid from healthy calves are positive for expression of
103 both the phagocytosis inhibitor, CD172a, and the LPS receptor, CD14. Conversely, very few
104 of these cells expressed the Fc receptor, CD16 [2]. These findings differ from those of human

105 studies which have shown that human AMs have low CD14 expression and are positive for
106 CD16 [15]. This study aimed to characterise bovine AMs further using multicolour flow
107 cytometry panels to detect the presence of various macrophage markers. Using novel
108 reagents, we show uniform expression of ADGRE1 on bovine BAL cells, low expression of
109 CX3CR1, and describe two major subsets of macrophages with differential expression of
110 CD163.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128 Materials and Methods

129 *Calves and sample collection*

130 The calves used in this study and the collection of BAL fluid has been previously
131 described [2]. All samples were taken with ethical approval from the Veterinary Ethics and
132 Review Committee at the Royal (Dick) School of Veterinary Studies in line with the Animal
133 Research: Reporting of In Vivo Experiments (ARRIVE) Guidelines [16]. Bronchoalveolar
134 lavage was performed on cadavers and is not classified as a regulated procedure under the
135 Animals (Scientific Procedures) Act, 1986 which governs animal studies in the UK. Briefly,
136 BAL samples were taken from Holstein-Friesian male calves aged between 12-24 days. The
137 calves were humanely euthanised by captive bolt and death was confirmed by auscultation.
138 The lungs were excised with the trachea intact and subsequently, lavage was performed by
139 pouring 1 L of sterile phosphate buffered saline (PBS) into the lungs via a funnel inserted into
140 the trachea. Lungs were massaged for 1 min before decanting the BAL fluid into a container.
141 The BAL fluid was processed further by filtering through a 70 µm filter, and cells were washed
142 and counted as previously described [17]. Cells were cryopreserved in Foetal Calf Serum
143 (Thermo Fisher Scientific; USA) containing 10 % DMSO (Sigma-Aldrich; USA) and stored at -
144 155 °C prior to characterisation by flow cytometry.

145

146 *Construction and production of ADGRE1 immunogens*

147 The cDNA of the N-terminal extracellular EGF-like domains for bovine
148 (ENSBTAT00000010390.6, e!Ensembl), ovine (ENSOART00000005245.1, e!Ensembl),
149 human (ENST00000312053.8, e!Ensembl) and rat (NM_001007557.1, NCBI) were
150 synthesized by Synbio Technologies and subsequently subcloned in frame into pFUSE–
151 hlgG1-Fc2 vector (Invivogen; San Diego, USA) using EcoRI-BglIII site for bovine, ovine and
152 human sequences and EcoRV-BglIII site for the rat sequence. Recombinant protein production
153 was carried out as previously described [6].

154

155 *Generation of anti-bovine ADGRE1 monoclonal antibody (mAb)*

156 This work was carried out under the authority of a UK Home Office Project License under the
157 regulations of the Animals (Scientific Procedures) Act 1986, with approval from the Roslin
158 Institute Animal Welfare and Ethics Committee. Balb/c mice (Charles River Laboratories, UK)
159 received three subcutaneous immunisations, 21 days apart comprising 50 µg protein (12.5 µg
160 each of ovine, bovine, rat ADGRE1 and human EMR1 protein in PBS) with TiterMax Gold
161 adjuvant (Merck, UK) in maximum volume of 100 µl. A final intraperitoneal injection with 50
162 µg protein (as above) in PBS was provided 4 days prior to cull. Cells were flushed from the
163 spleens with RPMI1640 supplemented with Glutamax (both Gibco, USA), and were fused with
164 Sp2/0-Ag14 mouse myeloma cells (CRL-1581; ATCC) at a ratio of 5:1, as previously described
165 [18].

166 An indirect ELISA, as previously described [18], against recombinant ovine, bovine, rat
167 ADGRE1 and human EMR1 Fc fusion protein (all at 50 ng per well) was used to identify
168 hybridomas which were producing specific antibodies. Recombinant human IgG Fc protein
169 was used to discriminate non-specific reactivity to the human-IgG1-Fc fusion tag. Positive
170 hybridoma cells were expanded and subcloned by serial dilution [18]. Supernatants from
171 expanded clones were purified by Protein G HiTrap column (Merck, UK), with buffer exchange
172 carried out using Slide-A-Lyzer™ G2 Dialysis Cassettes 1–3 mL 10 K MWCO (Thermo Fisher
173 Scientific, UK). The isotype was determined using the IsoStrip mouse monoclonal antibody
174 isotyping kit (Roche, UK).

175

176 *Generation of bovine CX3CL1*

177 The DNA sequence encoding bovine CX3CL1 was flanked with EcoRI (GAATTC) and
178 BglII (AGATCT) restriction sites. The designed DNA fragment was synthesized by Synbio
179 Technologies (Monmouth Junction, USA) and was subsequently cloned into the vector

180 pFUSE-hlgG1-FC1 (Invivogen; San Diego, USA). The restriction enzymes EcoRI and BglII
181 were both supplied by New England Biolabs (Hitchin, UK). The pFUSE-CX3CL1-FC1 was
182 transformed into chemically competent Escherichia coli DH5 α , using a standard heat-shock
183 protocol. Transformed bacteria were recovered for 1 hour in LB media at 37 °C, with shaking
184 at 180 rpm, prior to plating on LB media agar supplemented with 25 μ g/ml Zeocin (ant-zn-05;
185 Invivogen; San Diego, USA). All further growth of the transformed bacteria occurred in LB
186 media supplemented with 25 μ g/ml Zeocin. Sanger sequencing (Eurofinsgenomics;
187 Ebersberg, Germany) was used to confirm correct insertion and sequence of the CX3CL1 in
188 the final expression vector. DNA was prepared for transfection, in accordance with the
189 manufacturer's instructions, using an Endofree Maxiprep kit (Qiagen; Manchester, UK) and
190 the DNA was resuspended in 1x TE buffer prior to quantification by a Nanodrop
191 Spectrophotometer (Thermo Fisher Scientific; Perth, UK). Mycoplasma free HEK293T cells
192 used for transfection were cultured prior to use in DMEM (Merck; Darmstadt, Germany),
193 supplemented with 8 % Ultra Low IgG foetal bovine serum (Thermo Fisher Scientific; Perth,
194 UK) and Glutamax (Thermo Fisher Scientific; Perth, UK) at 37°C /5 % CO₂. For each flask
195 used, 90 μ g of DNA was complexed with 90 μ l of Lipofectamine 2000 (Thermo Fisher
196 Scientific; Perth, UK) in Opti-MEM reduced serum media (Thermo Fisher Scientific; Perth, UK)
197 for 10 minutes at room temperature. Transfections were allowed to proceed for 5 days before
198 supernatants were harvested. Supernatants were cleared by centrifugation at 375 x g and
199 filtered through a 0.45 μ m and 0.22 μ m low protein binding filter (Millipore; Livingston, UK)
200 prior to application to a 1 ml HiTrap protein G HP column (HP 17-0404-01; Cytivia; Little
201 Chalfont, UK) which had been stripped with 5x column volumes of 0.1 M Glycine pH 2.6 and
202 washed/equilibrated with 10x column volumes of PBS prior to use. For all steps a flow rate of
203 1 ml/min was used. Following binding of the expressed protein to the protein G, the column
204 was washed with 10x column volumes of PBS. Bound protein was eluted from the column in
205 1 ml fractions, using 0.1 M Glycine pH 2.7. Each fraction collected was neutralized by the
206 addition of 50 μ l of 1 M Tris pH 9.0. Fractions containing protein were identified using a
207 Nanodrop Spectrophotometer (Thermo Fisher Scientific; Perth, UK), pooled and then buffer

208 exchanged into sterile PBS using a 30 kDa MW cut-off Amicon Ultra-4 centrifugation filter unit
209 (Merck; Darmstadt, Germany). The final concentration of CXC3L1 was determined using a
210 Nanodrop Spectrophotometer (Thermo Fisher Scientific; Perth, UK) and fluorescently labelled
211 using Molecular Probes Alexa Fluor 647 conjugation kit (Thermo Fisher Scientific; USA)
212 according to manufacturer's instructions.

213 *Flow cytometry*

214 Primary monoclonal antibodies (mAbs) were conjugated to fluorophores using either
215 the Molecular Probe kit (Thermo Fisher Scientific; USA) for Pacific Blue, Alexa Fluor 488
216 (AF488), Alexa Fluor 568 (AF568) and Alexa Fluor 647 (AF647), or the Lightning Link kit
217 (Abcam; UK) for PE-Cy5, PE-Cy7, and PerCP-Cy5.5. Each conjugated reagent was titrated
218 to determine an optimal dilution (Table 1).

219 Cryopreserved cells were thawed and washed in PBS, and the number of viable cells
220 calculated using a haemocytometer and Trypan blue (Sigma-Aldrich; USA). Cells were
221 resuspended in blocking buffer (PBS with 5 % normal goat serum) to give 1×10^6 cells per well.
222 Cells were incubated with primary mAbs, diluted in blocking buffer for 30-60 minutes on ice,
223 followed by three PBS washes. Secondary antibody was diluted in PBS before being added
224 as indicated and incubated on ice for 30-60 minutes. This was followed by a further three PBS
225 washes, and the addition of Zombie NIR viability dye (Biolegend; USA) at a 1:2000 dilution in
226 PBS. After 20 minutes incubation at room temperature, cells were washed twice in PBS and
227 flow cytometric analysis carried out using a LSRFortessa flow cytometer (BD Biosciences;
228 USA). A minimum of 50,000 live, single cells were recorded for each sample.

229 The exact concentrations of the in-house conjugated antibodies were unknown;
230 therefore, it was not possible to include concentration-matched isotype controls. However,
231 before the cells were stained with the panels, flow cytometric analysis was carried out on
232 unconjugated versions of the antibodies with the inclusion of concentration-matched isotype
233 controls. This confirmed the absence of any non-specific binding (data not shown).

234 *Data Analysis*

235 All flow cytometry data was analysed using FlowJo_v10 software (BD Biosciences;
236 USA). Compensation was first calculated and applied to all samples. Gates were drawn to
237 exclude debris, doublets and select for viable cells (Supplementary Fig. 1). FMO controls were
238 included in all panels to enable gates to be drawn which separated the positive and negative
239 populations. Quadrants were applied to bivariate dot-plots of fluorescence data to determine
240 whether the cells were single positive, double positive, or double negative (Supplementary
241 Fig. 2). Microsoft Excel was used to produce all tables.

242 *Statistical Analysis*

243 Differences between expression of the surface molecules on the CD163⁺ and CD163⁻
244 subsets of AMs were assessed using a two-tailed paired Students' T-test in Excel. *p* values of
245 <0.05 were considered significant.

246

247 Results

248 *Bovine AMs express high levels of CD172a, ADGRE1, CD206 and CD14, and lower levels of*
249 *CD80, MHC II, CD1b, CD40 and CX3CR1*

250 The aim of this study was to characterise the AM populations in calf BAL fluid using
251 multicolour flow cytometry to detect the presence of various cell surface expressed molecules.

252 All four BAL samples were shown to have high autofluorescence and this prevented
253 clear distinction of positive cells from negative cells, making it difficult to accurately calculate
254 the percentage of cells which were positive for each molecule. Although the quadrants based
255 on the FMO controls may underestimate the true proportion of positive cells (Supplementary
256 Fig. 2), we assessed the degree of cell surface marker expression by calculating the change
257 in median fluorescent intensity (MFI) values (Table 2), and considering the position of the
258 histogram peaks of stained compared to unstained cells (Fig. 1).

259 Three of the four BAL samples expressed high levels of CD172a (Fig. 1a). The BAL
260 samples showed consistently high proportions of cells expressing ADGRE1 (Fig. 1b), CD206
261 (Fig. 1c), and CD14 (Fig. 1d). The expression of these molecules showed mean changes in
262 MFI above 1,100 (Table 2), and had large histogram peak shifts between the unstained and
263 stained cells. The shifts in histogram peaks were more modest for CD80 (Fig. 1e), MHC II
264 (Fig. 1f), CD1b (Fig. 1g), and CD40 (Fig 1h), with mean changes in MFI between 500 and
265 1,100 (Table 2). These molecules were therefore classed as moderately expressed. There
266 were low levels of CX3CR1 (Fig. 1i) and CD86 (Fig. 1j) which showed minimal shifts in the
267 histogram peaks, and had mean changes in MFI below 500 (Table 2). The majority of cells
268 appeared to be positive for CX3CR1 however, despite the low MFI. Little or no expression of
269 CD16 (Fig. 1k) and CD26 (Fig. 1l) was evident. In contrast to the above molecules which did
270 not appear to be expressed on subsets of BAL cells, there were two clear histogram peaks of
271 CD163 (Fig. 1m) in the BAL samples, indicating the presence of distinct CD163⁺ and CD163⁻
272 subsets.

273 *Subsets of bovine AMs differentially express CD163*

274 Cells were gated into CD163⁺ and CD163⁻ subpopulations for further analysis (Fig. 2)
275 and the mean change in MFI for cell surface expressed molecules within each subset
276 calculated (Table 3). The majority of cells were CD163⁺ (Fig. 2b; *Mean* = 66.2%, *SD* = 5.3%).
277 In all BAL samples, the CD163⁺ population had significantly higher levels of CD172a,
278 ADGRE1, CD206, CX3CR1, CD14, MHC II, CD26, and CD16 in comparison to the CD163⁻
279 cells. These differences appear not to be due to the intrinsic cell properties because the light
280 scattering levels from both the CD163⁺ and CD163⁻ populations were very similar in terms of
281 forward scatter (FSC) and side scatter (SSC) (Fig. 2c). CD80, CD86, CD1b, and CD40 were
282 not included on the same analysis panel as CD163 and therefore differential expression of
283 these markers was not assessed. Further analysis of CD172a (Fig. 3a) showed large
284 differences in expression between the CD163⁻ and CD163⁺ subsets. CD172a versus ADGRE1
285 staining was assessed on both CD163⁻ and CD163⁺ subsets (Fig. 3b), and the CD163⁺ subset

286 demonstrated greater expression of both CD172a and ADGRE1 in comparison to the CD163⁻
287 subset. In the CD163⁻ subset, a small ADGRE1⁻ population was observed, predicted to be
288 lymphocytes (Fig. 3b).

289 *Subsets of BAL myeloid cells differentially expressed CD163 and CD14*

290 To determine the presence of classical and non-classical myeloid cell populations,
291 expression of CD14, CD16 and CD163 on BAL was investigated further (Fig. 4). When cells
292 were examined for co-expression of CD163 and CD14, there were two subsets of
293 CD163⁺CD14⁺ cells (*Mean* = 39.1%, *SD* = 9.1%) and CD163⁻CD14⁻ cells (*Mean* = 34.5%, *SD*
294 = 8.0%) (Fig. 4a) observed. As previously indicated in Fig. 1k, little or no CD16 expression
295 was observed (Fig. 4b, c).

296

297 Discussion

298 Bovine AMs are the first line of defence against inhaled pathogens such as *M. bovis*,
299 however, little is known about the phenotype and heterogeneity of bovine AMs. This study
300 describes the cell surface phenotype of bovine AMs, including the expression of two molecules
301 for which we have recently generated reagents: ADGRE1 and CX3CR1. As described in
302 porcine AMs [6], ADGRE1 was expressed on the vast majority of bovine AMs at a high level.
303 Conversely, expression of CX3CR1 by bovine AMs was uniformly low.

304 Although F4/80 is expressed by many murine macrophage types, there is very little
305 expression by murine AMs [4]. Conversely, we found that bovine AMs have uniformly high
306 expression of ADGRE1, comparable to porcine AMs [6]. Although studies in F4/80 deficient
307 mice suggest that ADGRE1 may be involved in immune tolerance [19], in pigs, the rapid
308 evolution of this molecule and related ADGRE family members suggested immune selection
309 and a role in pathogen recognition [6]. Further studies are required to determine roles for
310 ADGRE1 in cattle.

311 We demonstrated here that the bovine AM population consists of distinct CD163⁺ and
312 CD163⁻ subsets. Similarly, human AMs can be divided into CD163 high and CD163
313 intermediate subsets [11]. It has been suggested that the diversity in CD163 expression in
314 human AMs may be an indication of whether the cells have foetal monocyte origins, or have
315 been derived from circulating monocytes. It is also possible that CD163 expression correlates
316 to the activation state or where the macrophage is localised within the lung [11]. Unlike human
317 and bovine AMs, pig AMs have been shown to be uniformly CD163⁺ [20].

318 CD163 is a scavenger receptor exclusively expressed by monocytes and
319 macrophages, and it has been used as a marker for anti-inflammatory M2 macrophages. To
320 our knowledge, the functions of CD163 in bovine AMs have not been examined. Further
321 investigations are required to determine potential roles in bovine health and disease. In our
322 study, high expression of CD163 corresponded with increased expression of other
323 macrophage markers in comparison to the CD163⁻ subset. Interestingly, MHC II was the
324 molecule with the most statistically significant difference in expression between the CD163⁺
325 and CD163⁻ subsets. This suggests that the CD163⁺ subset may be more efficient at antigen
326 presentation than the CD163⁻ cells.

327 Traditionally, macrophages have been classed as either belonging to the pro-
328 inflammatory M1 class or the anti-inflammatory M2 class. In mouse and humans, MHC II is
329 considered an M1 marker, whereas CD163 is considered an M2 marker. However, the
330 appropriateness of the M1/M2 categorisation for AMs has been questioned as it has been
331 shown that most human AMs have high expression levels of both M1 and M2 markers [21].
332 The vast majority of human AMs were categorised as CD206^{hi}CD86^{hi}, and this population also
333 had higher levels of CD163, CD80, CD64 and HLADR compared to the other subsets. It has
334 been suggested that this mixture of M1 and M2 features may allow AMs to maintain a balance
335 between immunological protection and tolerance [21]. Whilst the M1/M2 categorisation has
336 been studied extensively in humans and mice, macrophage polarisation in cattle has been
337 less explored. In this study, we showed that bovine AMs express a mixture of molecules

338 categorised as M1 and M2 markers. There were high expression levels of the M2 marker,
339 CD206, and moderate expression levels of the M1 markers, CD80, MHC II, and CD40. Further
340 studies of function will be required to elucidate functional roles for bovine AM subsets and
341 determine whether they can be classified according to the M1/M2 paradigm.

342 Tissue resident AMs originate from foetal monocytes that colonise the lungs soon after
343 birth. Whilst these AMs are capable of self-renewal, they can also be replenished by circulating
344 monocytes. Therefore, in this study we analysed the expression of markers expressed by
345 monocytes. It has been shown that bovine monocytes, like human monocytes, can be divided
346 into three groups based upon the expression of CD14, CD16, and CD163. The majority of
347 monocytes in the peripheral blood of cattle are classical monocytes (CD14⁺CD16⁻CD163^{hi}).
348 There are also intermediate monocytes (CD14⁺CD16⁺) and non-classical monocytes (CD14⁻
349 CD16⁺CD163^{lo}) [22; 9]. In this study it was shown that bovine AMs can be divided into two
350 populations of CD163⁺CD14⁺ cells and CD163⁻CD14⁻ cells, both of which were CD16⁻. The
351 CD163⁺CD14⁺ population, therefore, resembles the classical monocyte population.

352 It is likely that the three bovine monocyte subsets have different functions, however,
353 different studies have yielded contradictory results due to differences in isolation techniques
354 and gating strategies. For example, one study demonstrated that non-classical bovine
355 monocytes are not inflammatory as their ability to phagocytose material, generate reactive
356 oxygen species (ROS), and express LPS-induced IL-1 β is reduced compared to the other
357 subsets [22]. However, another study showed that non-classical monocytes had a greater
358 endocytic capability compared to the other subsets, and expressed high levels of IL-1 β upon
359 stimulation [9]. Bovine monocyte subsets were shown to have different expression levels of
360 chemokine receptors and antigen presentation and costimulatory molecules, indicating that
361 they have different roles in detecting pathogens and processing antigens. For example, it was
362 shown that classical monocytes have greater CD86 expression but lower CD1b and CX3CR1
363 expression compared to non-classical monocytes [9]. In our study, bovine AMs were shown
364 to have low CD86 and CX3CR1 expression, and moderate CD1b expression. Interestingly,

365 CX3CR1 was expressed at greater levels in the CD163⁺ subset compared to the CD163⁻
366 subset. Although the CD163⁺ CD14⁺ subset would appear to correlate with the classical
367 monocyte population, CX3CR1 expression is greater in non-classical monocytes compared to
368 classical monocytes.

369 The analysis of AMs by flow cytometry was challenging due to the high
370 autofluorescence of the cells which made it difficult to accurately apply gating boundaries to
371 distinguish positive and negative populations. Additional analysis of the cell subsets will be
372 required to determine functional capabilities of the subsets and expression of additional key
373 molecules. The BAL samples used in this study were extracted from male Holstein-Friesian
374 calves between the ages of 12-24 days. It has been reported that bovine AMs mature during
375 the first 3 to 6 months of life, and during this maturation period there are fluctuations in the
376 number of CD14⁺ cells and the efficiency with which they carry out phagocytosis and generate
377 ROS [23]. Therefore, expression of some molecules by AMs may differ in neonates and adult
378 cattle, requiring additional study particularly in the context of chronic diseases such as bovine
379 tuberculosis.

380 Here we have extended the phenotypic analysis of bovine AMs and have described
381 the presence of two major subsets with differential CD163 expression. This characterisation
382 of uninfected bovine AMs is essential for future studies which will examine the role of AMs in
383 *M. bovis* infection.

384

385 **Data Availability**

386 Data supporting the findings of the study are available within the paper and its supplementary
387 information.

389 **References**

- 390 1. Queval, C. J., Brosch, R. and Simeone, R. The macrophage: A disputed fortress in the
391 battle against *Mycobacterium tuberculosis*. *Front. Microbiol.* **8**, 2284 (2017).
- 392 2. Kolar, Q. K., et al. Anatomical distribution of respiratory tract leukocyte cell subsets in
393 neonatal calves. *Vet. Immunol. Immunopathol.* **227**, 110090 (2020).
- 394 3. Gordon, S., Hamann, J., Lin, H. and Stacey, M. F4/80 and the related adhesion-GPCRs.
395 *Eur. J. Immunol.* **41**, 2472-2476 (2011).
- 396 4. Dos Anjos Cassado, A. F4/80 as a major macrophage marker: The case of the
397 peritoneum and spleen. *Results Probl. Cell Differ.* **62**, 161-179 (2017).
- 398 5. Zhang, X., Goncalves, R. and Mosser, D. M. The isolation and characterization of murine
399 macrophages. *Curr. Protoc. Immunol.* **83**, 14.1.1-14.1.14 (2008).
- 400 6. Waddell, L. A., et al. ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in
401 mammalian monocyte-macrophages. *Front. Immunol.* **9**, 2246 (2018).
- 402 7. Lee, M., et al. Tissue-specific role of CX3CR1 expressing immune cells and their
403 relationships with human disease. *Immune Netw.* **18**, e5 (2018).
- 404 8. Burgess, M., et al. Cx3CR1 expression identifies distinct macrophage populations that
405 contribute differentially to inflammation and repair. *Immunohorizons* **3**, 262-273 (2019).
- 406 9. Corripio-Miyar, Y., et al. Phenotypic and functional analysis of monocyte populations in
407 cattle peripheral blood identifies a subset with high endocytic and allogeneic T-cell
408 stimulatory capacity. *Vet. Res.* **46**, 112 (2015).
- 409 10. Schyns, J., Bureau, F. and Marichal, T. Lung interstitial macrophages: past, present, and
410 future. *J. Immunol. Res.* **2018**, 5160794 (2018).

- 411 11. Bharat, A., et al. Flow cytometry reveals similarities between lung macrophages in
412 humans and mice. *Am. J. Respir. Cell. Mol. Biol.* **54**, 147-149 (2016).
- 413 12. Aggarwal, N. R., King, L. S. and D'Alessio, F. R. Diverse macrophage populations
414 mediate acute lung inflammation and resolution. *Am. J. Physiol.* **306**, 709-725 (2014).
- 415 13. Murphy, K. and Weaver, C. *Janeway's Immunobiology*. 9th edition. (Garland Science,
416 2017).
- 417 14. Mould, K. J., et al. Single cell RNA sequencing identifies unique inflammatory airspace
418 macrophage subsets. *JCI Insight.* **4**, e126556 (2019).
- 419 15. Evren, E., Ringqvist, E. and Willinger, T. Origin and ontogeny of lung macrophages: from
420 mice to humans. *Immunol.* **160**, 126-138 (2020).
- 421 16. Percie du Sert, N., et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting
422 animal research. *PLoS Biol.* **18**, e3000410 (2020).
- 423 17. Kapetanovic, R., et al. The impact of breed and tissue compartment on the response of
424 pig macrophages to lipopolysaccharide. *BMC Genomics* **14**, 581 (2013).
- 425 18. Waddell, L. A., et al. A novel monoclonal antibody against porcine macrophage colony-
426 stimulating factor (CSF1) detects expression on the cell surface of macrophages. *Vet.*
427 *Immunol. Immunopathol.* **266**, 110681 (2023).
- 428 19. Lin, H. H., et al. The macrophage F4/80 receptor is required for the induction of antigen-
429 specific efferent regulatory T cells in peripheral tolerance. *J. Exp. Med.* **201**, 1615-1625
430 (2005).
- 431 20. Liu, H., et al. Heterogeneity and plasticity of porcine alveolar macrophage and pulmonary
432 interstitial macrophage isolated from healthy pigs in vitro. *Biol. Open* **8**, bio046342 (2019).
- 433 21. Mitsi, E., et al. Human alveolar macrophages predominately express combined classical
434 M1 and M2 surface markers in steady state. *Respir. Res.* **19**, 66 (2018).

435 22. Hussen, J., et al. Phenotypic and functional heterogeneity of bovine blood monocytes.
436 *PLoS One* **8**, e71502 (2013).

437 23. Bertagnon, H. G., et al. Alveolar macrophage functions during the transition phase to
438 active immunity in calves. *J. Anim. Sci.* **96**, 3738–3747 (2018).

439

440 **Acknowledgements**

441 We gratefully acknowledge the expert assistance of staff at the University of Edinburgh
442 Large Animal Research Imaging Facility. We thank the Roslin Institute Bioimaging and Flow
443 Cytometry Facility staff for training and guidance on flow cytometry. EMR was funded by an
444 EASTBIO PhD Studentship (BB/T00875X/1). JCH, LAW, ID, AR and TB were funded by
445 BBSRC Institute Strategic Programme funding (BBS/E/RL/230002B, BBS/E/D/10002071,
446 BBS/E/D/20002174). The bovine ADGRE1 and CX3CL1 reagents were produced by The
447 Roslin Immunological Toolbox which is supported by funding from BBSRC (BB/CCG2270/1).

448

449 **Author Contributions**

450 EMR: Investigation, Data analysis, Writing. PS: Data analysis. AR: Data analysis. ID:
451 Methodology. TB: Supervision. JCH: Conceptualisation, Supervision. LAW: Supervision,
452 Data analysis. All authors reviewed the manuscript.

453

454 **Additional Information**

455 The authors declare that they have no competing interests.

456

457

458

459

460

461 **Figure Legends**

462 **Figure 1: Expression of cell surface molecules by BAL Cells.** Bovine BAL cells were
463 stained for expression of the cell surface molecules shown and assessed by flow cytometry.
464 Live, single cells were gated as described in Supplementary Figures 1 and 2. Expression
465 levels of each molecule are shown in blue histograms with unstained cells shown in red. One
466 representative example of n = 4 biological replicates.

467 **Figure 2: Subsets of BAL differentially express CD163.** BAL cells were stained for
468 expression of a range of cell surface molecules and assessed by flow cytometry. Live, single
469 cells were gated as shown in Supplementary Figure 1. **(a)** The FMO-CD163 control was used
470 to draw a gate to separate cells into CD163⁺ and CD163⁻ subsets. **(b)** These gates were
471 applied to the stained samples. **(c)** back-gating onto the FSC-A vs SSC-A plot showed that
472 the CD163⁻ cells (red) and CD163⁺ cells (blue) were of a similar size. One representative
473 example of n = 4 biological replicates.

474 **Figure 3: Differential expression of CD172a by CD163⁺ and CD163⁻ BAL cells.** BAL cells
475 were stained for expression of a range of cell surface molecules and assessed by flow
476 cytometry. Live, single cells were gated as shown in Supplementary Figure 1 and gates were
477 set as in Supplementary Figure 2. Cells were further gated based on expression of CD163 as
478 shown in Figure 2. **(a)** CD172a fluorescence intensities for the CD163⁻ subset (red) and the
479 CD163⁺ subset (blue). **(b)** The cells were separated into CD163⁺ and CD163⁻ subsets before
480 applying the CD172a vs ADGRE1 gate. One representative example of n = 4 biological
481 replicates.

482 **Figure 4: Two major populations of BAL cells are distinguished on the basis of CD163**
483 **and CD14 expression.** BAL cells were stained for expression of a range of cell surface
484 molecules and assessed by flow cytometry. Live, single cells were gated as shown in

485 Supplementary Figure 1 and gates were set as described in Supplementary Figure 2. **(a)**

Molecule	Clone	Species	Conjugate	Isotype	Optimal dilution	Source	Secondary antibody
CD172a	ILA24	Mouse anti-bovine	Pacific Blue	IgG1	1:100	RI Toolbox	N/A
ADGRE1	1F6/1A6	Mouse anti-bovine	AF488	IgG1	1:500	RI Toolbox	N/A
CD163	LND68A	Mouse anti-bovine	PerCP-Cy5.5	IgG1	1:2,000	Kingfisher, USA	N/A
CD26	CC69	Mouse anti-bovine	AF568	IgG1	1:100	BioRad, USA	N/A
CD206	122D2.08	Mouse anti-human	None	IgG1	1:2,500 (0.2ug/ml)	Dendritics, France	Rat anti-mouse IgG1 Clone: RMG1-1 Conjugate: PE-Cy7 Dilution: 0.01ug/ml Source: BioLegend, USA
CX3CR1			AF647		1:50	RI Toolbox	N/A
MHC II	ILA21	Mouse anti-bovine	AF488	IgG2a	1:200	RI Toolbox	N/A
CD86	IL-A190	Mouse anti-bovine	PerCP-Cy5.5	IgG1	1:200	RI Toolbox	N/A
CD80	IL-A159	Mouse anti-bovine	AF568	IgG1	1:200	RI Toolbox	N/A
CD1b	CC122	Mouse anti-bovine	None	IgG1	1:1,000	RI Toolbox	Rat anti-mouse IgG1 Clone: RMG1-1 Conjugate: PE-Cy7 Dilution: 0.01ug/ml Source: BioLegend, USA
CD40	IL-A158	Mouse anti-bovine	AF647	IgG1	1:400	RI Toolbox	N/A
CD16	KD1	Mouse anti-human	FITC	IgG2a	1:200 (5ug/ml)	BioRad, USA	N/A
CD14	CC-G33	Mouse anti-bovine	AF568	IgG1	1:200	BioRad, USA	N/A

486 CD163 vs CD14, **(b)** CD16 vs CD14, **(c)** CD16 vs CD163. One representative example of n =

487 4 biological replicates.

488 **Tables**

489 **Table 1: Antibodies used for multicolour flow cytometry analysis.** Abbreviations RI
490 Toolbox: Roslin Institute Toolbox; N/A not applicable

491

492

493

	Mean change in MFI	SD
CD172a	3,278.3	1,806.6
ADGRE1	3,462.8	1,098.4
CD206	2,706.0	694.4
CD14	1,189.5	393.6
CD80	1,069.5	118.3
MHCII	790.0	88.8
CD1b	742.5	152.2
CD40	614.3	301.2
CX3CR1	397.0	97.5
CD86	292.3	19.4
CD16	178.8	123.2
CD26	36.0	23.8

494 **Table 2: Mean (\pm SD) change in MFI for cell surface expressed molecules comparing**

	CD163+		CD163-		p-value
	Mean change in MFI	SD	Mean change in MFI	SD	
CD163	6,230.3	1,417.9	201.0	93.7	0.004**
CD172a	4,307.0	2,242.0	1,431.5	848.6	0.027*
ADGRE1	4,487.5	1,328.8	1,982.0	525.8	0.010*
CD206	3,481.3	819.8	1,129.5	226.8	0.005*
CD14	2,086.3	415.9	326.0	158.4	0.001**
MHCII	710.3	44.4	322.0	42.4	<0.001***
CX3CR1	545.3	139.8	135.0	27.2	0.013*
CD16	265.5	145.7	70.0	84.1	0.019*
CD26	108.0	52.0	-83.3	56.6	0.032*

495 **unstained and stained cells. n = 4 biological replicates.**

496

497

498 **Table 3: Mean (\pm SD) change in MFI for a range of molecules on CD163⁺ and CD163⁻ BAL**
 499 **cells. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 statistically**
 500 **significant difference between molecule expression on CD163⁺ and CD163⁻ BAL cells**
 501 **by two-tailed paired Students' T-test. n = 4 biological replicates.**